These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 7796290)

  • 41. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience.
    Peyromaure M; Delongchamps NB; Debré B; Zerbib M
    Urology; 2005 Apr; 65(4):724-9. PubMed ID: 15833516
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Androgen deprivation therapy in locally advanced prostate cancer].
    Rossi D; Beuzeboc P; Staerman F; Timsit MO; Benchikh El Fegoun A
    Prog Urol; 2010 Mar; 20 Suppl 1():S68-71. PubMed ID: 20493450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
    Lam ET; Glodé LM
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Practice patterns for post-prostatectomy hormonal therapy amongst Canadian radiation oncologists.
    Baxi S; Catton C
    Can J Urol; 2010 Dec; 17(6):5436-41. PubMed ID: 21172106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of neoadjuvant androgen deprivation prior to radical prostatectomy.
    Fradet Y
    Urol Clin North Am; 1996 Nov; 23(4):575-85. PubMed ID: 8948412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Aspects for hormone therapy in prostate cancer].
    Gorski J; Böhm WD; Kelly LU
    Z Urol Nephrol; 1981 Sep; 74(9):635-41. PubMed ID: 7314984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biology of castration-recurrent prostate cancer.
    Azzouni F; Mohler J
    Urol Clin North Am; 2012 Nov; 39(4):435-52. PubMed ID: 23084522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant and adjuvant therapies in prostate cancer.
    Schutz FA; Oh WK
    Urol Clin North Am; 2010 Feb; 37(1):97-104, Table of Contents. PubMed ID: 20152523
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Controversies of androgen ablation therapy for metastatic prostate cancer.
    Wilson SS; Crawford ED
    Curr Pharm Des; 2006; 12(7):799-805. PubMed ID: 16515496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Androgen deprivation in combination with radical prostatectomy for localized prostate cancer.
    Naito S
    Int J Urol; 2001 Jul; 8(7):S19-21. PubMed ID: 11442672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary.
    Abbas F; Scardino PT
    Urol Clin North Am; 1996 Nov; 23(4):587-604. PubMed ID: 8948413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate cancer treatment.
    Am Fam Physician; 1983 Dec; 28(6):237-41. PubMed ID: 6650340
    [No Abstract]   [Full Text] [Related]  

  • 55. Re: Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Neulander EZ
    J Urol; 2004 Feb; 171(2 Pt 1):809; author reply 809-10. PubMed ID: 14713828
    [No Abstract]   [Full Text] [Related]  

  • 56. Editorial comment on: Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting.
    Aus G
    Eur Urol; 2007 Oct; 52(4):1043. PubMed ID: 17933028
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy.
    Liow E; Howard N; Jung CH; Pope B; Campbell BK; Nguyen A; Kerger M; Ruddle JB; Anton A; Thomas B; Chu K; Dundee P; Peters JS; Costello AJ; Ryan AS; Hovens CM; Tran B; Corcoran NM
    Clin Genitourin Cancer; 2022 Oct; 20(5):452-458. PubMed ID: 35688680
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The value of neoadjuvant therapy in localized prostate cancer.
    Witjes WP; Oosterhof GO; Schaafsma HE; Debruyne FM
    Int J Urol; 1995 Mar; 2(1):1-5. PubMed ID: 7614403
    [No Abstract]   [Full Text] [Related]  

  • 59. Androgen deprivation therapy as primary treatment for prostate cancer.
    Cannata DH; Kirschenbaum A; Levine AC
    J Clin Endocrinol Metab; 2012 Feb; 97(2):360-5. PubMed ID: 22162475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Diagnosis, treatment and follow up of prostata cancer].
    Birkhäuser FD; Thalmann GN
    Ther Umsch; 2008 Jun; 65(6):323-8. PubMed ID: 18622955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.